niacinamide has been researched along with Hemangioendothelioma, Epithelioid in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hemangioendothelioma, Epithelioid: A tumor of medium-to-large veins, composed of plump-to-spindled endothelial cells that bulge into vascular spaces in a tombstone-like fashion. These tumors are thought to have borderline aggression, where one-third develop local recurrences, but only rarely metastasize. It is unclear whether the epithelioid hemangioendothelioma is truly neoplastic or an exuberant tissue reaction, nor is it clear if this is equivalent to Kimura's disease (see ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA). (Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have carried out a stratified phase II study of sorafenib (So) in patients with advanced angiosarcoma (n = 32) and epithelioid hemangioendothelioma (n = 13)." | 5.19 | Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. ( Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chevreau, C | 2 |
| Le Cesne, A | 2 |
| Ray-Coquard, I | 2 |
| Italiano, A | 2 |
| Cioffi, A | 1 |
| Isambert, N | 1 |
| Robin, YM | 2 |
| Fournier, C | 2 |
| Clisant, S | 2 |
| Chaigneau, L | 1 |
| Bay, JO | 2 |
| Bompas, E | 2 |
| Gauthier, E | 1 |
| Blay, JY | 2 |
| Penel, N | 2 |
| Bal-Mahieu, C | 1 |
| Baldeyrou, B | 1 |
| Lansiaux, A | 1 |
| Piperno-Neumann, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery[NCT00874874] | Phase 2 | 96 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Hemangioendothelioma, Epithelioid
| Article | Year |
|---|---|
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration | 2013 |
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, E | 2014 |